Compass Point Research to Collaborate With NDA Partners to Develop Migraine Combination Drug
Marketwired - Tue Apr 07, 4:00PM CDT
Lori Nesbitt, PharmD, Chief Executive Officer of Compass Point Research, announced today that the company has entered into an agreement with NDA Partners LLC, a highly regarded medical product development and regulatory strategy consultancy, to collaborate in the development of a new combination drug for the treatment of migraine headaches. Compass Point has been retained by the drug sponsor, MultiCorp International, Inc., a publicly traded company located in Sun Valley, CA, to manage the product development program, and NDA Partners will provide the drug development and regulatory expertise needed to prepare a development plan for a 505(b)(2) NDA submission to the US Food & Drug Administration (FDA) and to manage a preIND meeting with the FDA review division.
MultiCorp International, Inc. Engages Compass Point Research to Collaborate With NDA Partners to Develop Patented Migraine Combination Drug
Marketwired - Tue Mar 31, 8:02AM CDT
MultiCorp International, Inc, (OTC PINK: MCIC) has engaged Compass Point Research of Nashville, Tennessee to manage the product development program, and NDA Partners, of Rochelle, Virginia will provide the drug development and regulatory expertise needed to prepare a development plan for a 505(b)(2) NDA submission to the US Food & Drug Administration (FDA) and to manage a pre IND meeting with the FDA review division.